IL205624A - Carboxamide, Sulfonamide and Amine Compounds, Their Pharmaceutical Preparations - Google Patents

Carboxamide, Sulfonamide and Amine Compounds, Their Pharmaceutical Preparations

Info

Publication number
IL205624A
IL205624A IL205624A IL20562410A IL205624A IL 205624 A IL205624 A IL 205624A IL 205624 A IL205624 A IL 205624A IL 20562410 A IL20562410 A IL 20562410A IL 205624 A IL205624 A IL 205624A
Authority
IL
Israel
Prior art keywords
sulfonamide
carboxamide
medicaments
preparation
pharmaceutical compositions
Prior art date
Application number
IL205624A
Other languages
English (en)
Hebrew (he)
Other versions
IL205624A0 (en
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of IL205624A0 publication Critical patent/IL205624A0/en
Publication of IL205624A publication Critical patent/IL205624A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL205624A 2007-11-16 2010-05-09 Carboxamide, Sulfonamide and Amine Compounds, Their Pharmaceutical Preparations IL205624A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US98872107P 2007-11-16 2007-11-16
US99055407P 2007-11-27 2007-11-27
US99055807P 2007-11-27 2007-11-27
US99118907P 2007-11-29 2007-11-29
US1392407P 2007-12-14 2007-12-14
PCT/US2008/083801 WO2009065131A1 (en) 2007-11-16 2008-11-17 Carboxamide, sulfonamide and amine compounds for metabolic disorders

Publications (2)

Publication Number Publication Date
IL205624A0 IL205624A0 (en) 2010-11-30
IL205624A true IL205624A (en) 2016-10-31

Family

ID=40352415

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205624A IL205624A (en) 2007-11-16 2010-05-09 Carboxamide, Sulfonamide and Amine Compounds, Their Pharmaceutical Preparations

Country Status (15)

Country Link
US (3) US8119809B2 (https=)
EP (1) EP2231600B1 (https=)
JP (1) JP5544296B2 (https=)
KR (1) KR101573091B1 (https=)
CN (1) CN101910131B (https=)
AU (3) AU2008322426C1 (https=)
BR (1) BRPI0820171B8 (https=)
CA (1) CA2705947C (https=)
EA (1) EA019509B1 (https=)
ES (1) ES2552733T3 (https=)
IL (1) IL205624A (https=)
MX (2) MX382569B (https=)
NZ (1) NZ585298A (https=)
WO (1) WO2009065131A1 (https=)
ZA (1) ZA201003412B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2674237C (en) 2006-12-28 2015-11-24 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
BRPI0820171B8 (pt) 2007-11-16 2021-05-25 Rigel Pharmaceuticals Inc compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos
CA2707047C (en) * 2007-12-12 2017-11-28 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
MX2010011288A (es) 2008-04-23 2010-11-09 Rigel Pharmaceuticals Inc Compuestos de carboxamida para el tratamiento de trastornos metabolicos.
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
CN102365275B (zh) 2009-01-28 2014-09-24 里格尔药品股份有限公司 羧酰胺化合物及其使用方法
EP2438059A1 (en) 2009-06-05 2012-04-11 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
CN102666485A (zh) * 2009-09-21 2012-09-12 霍夫曼-拉罗奇有限公司 烯烃羟吲哚衍生物及其用于治疗肥胖症，糖尿病和高脂血症的应用
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130274185A1 (en) * 2010-03-16 2013-10-17 The University Of Tokyo Pharmaceutical for Pseudo-Exercise Therapy
WO2011123681A1 (en) 2010-03-31 2011-10-06 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
WO2011142359A1 (ja) * 2010-05-10 2011-11-17 日産化学工業株式会社 スピロ化合物及びアディポネクチン受容体活性化薬
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化学化合物
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
EP2630144B1 (en) 2010-10-19 2016-09-07 Boehringer Ingelheim International GmbH Rho kinase inhibitors
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9409884B2 (en) 2012-02-01 2016-08-09 Rigel Pharmaceuticals, Inc. 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6233855B2 (ja) * 2012-08-08 2017-11-22 ノバルティス・ティーアゲズントハイト・アクチェンゲゼルシャフトＮｏｖａｒｔｉｓ Ｔｉｅｒｇｅｓｕｎｄｈｅｉｔ Ａｇ 殺虫剤としての置換されたアジン類
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
EP4105208A1 (en) 2013-07-31 2022-12-21 Novartis AG 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions
US20160214967A1 (en) 2013-09-30 2016-07-28 The University Of Tokyo Activator of adiponectin receptor
KR20170090477A (ko) * 2014-12-08 2017-08-07 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피리딘카복스아미드 유도체, 그의 제조 방법 및 그의 약학적 용도
CN114206851B (zh) * 2019-04-26 2025-02-11 默沙东有限责任公司 可用于制备(2s,5r)-7-氧代-n-哌啶-4-基-6-(硫酸基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的中间体的制备方法
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820115D0 (en) * 1988-08-24 1988-09-28 Ici Plc Insecticidal compounds
US6137002A (en) * 1993-07-22 2000-10-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
EE9800335A (et) 1996-03-28 1999-04-15 Glaxo Group Limited Pürrolopürrolooni derivaadid kui neutrofiilelastaasi inhibiitorid
GB9715584D0 (en) 1997-07-23 1997-10-01 Eisai Co Ltd Compounds
DE19738615A1 (de) * 1997-09-04 1999-03-11 Clariant Gmbh Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
HK1047748B (zh) * 1999-10-08 2004-10-21 Grunenthal Gmbh 在第六环上取代的二环咪唑并-3-基-胺的衍生物
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
DE60137273D1 (de) * 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
US6875765B2 (en) 2001-05-10 2005-04-05 Warner-Lambert Company Arylsulfonamide ethers, and methods of use thereof
EP1419162A1 (en) 2001-08-24 2004-05-19 Pharmacia & Upjohn Company Substituted-aryl 7-aza 2.2.1]bicycloheptanes for the treatment of disease
JP2005527472A (ja) 2001-09-12 2005-09-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン
JP2005523288A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
CA2475773A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
AU2003254157A1 (en) * 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
BR0317230A (pt) 2002-12-13 2005-10-25 Smithkline Beecham Corp Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto
US7208491B2 (en) * 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
GB0314054D0 (en) 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
CA2549009A1 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
NZ550534A (en) * 2004-03-25 2009-07-31 Memory Pharm Corp Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
CA2566526C (en) 2004-06-02 2012-10-23 F. Hoffmann-La Roche Ag Naphthaline derivatives useful as histamine-3-receptor ligands
DK1761519T3 (da) * 2004-06-21 2008-07-21 Hoffmann La Roche Indolderivater som histaminreceptorantagonister
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
MX2007004465A (es) 2004-10-19 2007-05-07 Hoffmann La Roche Derivados de quinolina.
EP1807391A4 (en) 2004-10-29 2010-01-06 Astrazeneca Ab NOVEL SULFONAMIDE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP1813613B1 (en) 2004-11-08 2012-12-19 Msd K.K. Novel fused imidazole derivative
AU2005311251A1 (en) 2004-12-01 2006-06-08 Devgen Nv 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family
JP2008524255A (ja) 2004-12-17 2008-07-10 スミスクライン ビーチャム コーポレーション 化学物質
AP2334A (en) 2004-12-17 2011-12-06 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
US20060187891A1 (en) 2005-02-24 2006-08-24 Jussi-Pekka Sairanen Provision of services in a communication system
AU2006218403A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
ES2400287T3 (es) 2005-03-14 2013-04-08 High Point Pharmaceuticals, Llc Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa
TW200716628A (en) 2005-03-22 2007-05-01 Astrazeneca Ab Novel compounds
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
WO2007005951A2 (en) 2005-07-05 2007-01-11 Aryx Therapeutics, Inc. Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders
AU2006295397A1 (en) * 2005-09-23 2007-04-05 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
RU2008126391A (ru) * 2005-11-30 2010-01-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 1,5-замещенного индол-2-иламида
ATE507222T1 (de) * 2005-11-30 2011-05-15 Hoffmann La Roche 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren
DE602006014022D1 (de) * 2005-11-30 2010-06-10 Hoffmann La Roche 5-substituierte indol-2-carbonsäureamidderivate
MX2008008339A (es) * 2005-12-21 2008-09-03 Schering Corp Derivados de anilina sustituida ùtiles como antagonistas de la histamina h3.
JP2009524689A (ja) 2006-01-25 2009-07-02 スミスクライン ビーチャム コーポレーション 化合物
PE20070946A1 (es) 2006-01-25 2007-10-16 Smithkline Beecham Corp COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
WO2007098086A2 (en) 2006-02-17 2007-08-30 Avalon Pharmaceuticals Hydroxypiperidine derivatives and uses thereof
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
JP5190448B2 (ja) 2006-04-20 2013-04-24 ファイザー・プロダクツ・インク グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物
CA2651072A1 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
EP2032566A4 (en) 2006-06-12 2009-07-08 Merck Frosst Canada Ltd AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
WO2007143824A1 (en) 2006-06-13 2007-12-21 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
TW200821303A (en) 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
CA2674237C (en) * 2006-12-28 2015-11-24 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
JP2010527915A (ja) 2007-04-26 2010-08-19 アバロン ファーマシューティカルズ，インコーポレイテッド 多重環化合物及びその用途
PH12013501594A1 (en) * 2007-07-20 2014-05-12 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
BRPI0820171B8 (pt) 2007-11-16 2021-05-25 Rigel Pharmaceuticals Inc compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos
CA2707047C (en) 2007-12-12 2017-11-28 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EA018703B1 (ru) * 2008-04-07 2013-10-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
MX2010011288A (es) * 2008-04-23 2010-11-09 Rigel Pharmaceuticals Inc Compuestos de carboxamida para el tratamiento de trastornos metabolicos.
JP2010090067A (ja) * 2008-10-09 2010-04-22 Taisho Pharmaceutical Co Ltd 含窒素複素環誘導体

Also Published As

Publication number Publication date
BRPI0820171B1 (pt) 2021-02-23
CN101910131A (zh) 2010-12-08
IL205624A0 (en) 2010-11-30
CA2705947C (en) 2016-08-09
EP2231600A1 (en) 2010-09-29
US9174964B2 (en) 2015-11-03
AU2017202766B2 (en) 2019-03-21
WO2009065131A1 (en) 2009-05-22
MX2010005298A (es) 2010-06-30
NZ585298A (en) 2012-08-31
AU2014202572B2 (en) 2017-02-02
US20140051673A1 (en) 2014-02-20
AU2008322426C1 (en) 2014-10-23
US8119809B2 (en) 2012-02-21
ZA201003412B (en) 2011-02-23
CA2705947A1 (en) 2009-05-22
EA019509B1 (ru) 2014-04-30
KR101573091B1 (ko) 2015-11-30
BRPI0820171B8 (pt) 2021-05-25
JP2011503210A (ja) 2011-01-27
ES2552733T3 (es) 2015-12-01
EA201070619A1 (ru) 2010-12-30
CN101910131B (zh) 2014-04-23
AU2014202572A1 (en) 2014-06-05
AU2008322426A1 (en) 2009-05-22
MX382569B (es) 2025-03-13
AU2008322426B2 (en) 2014-06-05
US20090170829A1 (en) 2009-07-02
JP5544296B2 (ja) 2014-07-09
HK1148525A1 (en) 2011-09-09
US8569340B2 (en) 2013-10-29
US20120115838A1 (en) 2012-05-10
AU2017202766A1 (en) 2017-05-18
KR20100097695A (ko) 2010-09-03
EP2231600B1 (en) 2015-07-29

Similar Documents

Publication Publication Date Title
IL205624A (en) Carboxamide, Sulfonamide and Amine Compounds, Their Pharmaceutical Preparations
IL274602B (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and their use in the preparation of drugs for the treatment of thrombocytopenia
IL193762A (en) The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs
IL202840A (en) Preserved pyridinone n-aryl, pharmaceuticals including them and their use in the manufacture of drugs to treat fibrosis-mediated disorders and collagen-mediated disorders
IL202515A (en) Thyroid-like compounds and their use in the preparation of drugs for the treatment of @ metabolic diseases
IL211028A (en) Solid Pharmaceutical Preparations Containing Linclutidine, Cationic and Reliable Primary Sterile Disorder
IL189578A (en) Pyridine derivatives, pharmaceutical compounds containing them, and their use in the preparation of drugs for the treatment of cns diseases
IL219437A (en) Converted benzamide histories, processes for their preparation, pharmacological compounds containing them and their use in the preparation of drugs for the treatment of cardiovascular diseases
IL181734A (en) Surapnib Tosylate Polymorph, Pharmaceuticals Containing It and Using It to Make Medicines
TWI369987B (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
IL184148A (en) History of triazole is claimed as oxytocin antagonists, their pharmacological preparations and their use in the preparation of drugs for the treatment of disorders in which the inhibition of oxytocin gives a beneficial effect
IL202158A (en) History of Oxadiazole, Pharmaceuticals Containing Them and Their Use in the manufacture of Drugs for the Treatment of Neurological and Psychiatric Disorders
IL193678A (en) Derivatives of pyrazolyl-theophane, pharmaceuticals containing them and their use in the preparation of drugs to improve cognitive activity
IL204887A (en) Acetamide History, Pharmaceuticals Containing Them, Methods of Preparing and Using It in the Preparation of Diabetes Medications
IL212573A (en) Aryl Methyl Benzokinazulinone Compounds
IL199187A (en) Indole history, pharmaceuticals including them and their use in the manufacture of medicines
IL234166B (en) Isoindoline compounds, a pharmaceutical composition containing it and its use in the preparation of a medicine
IL200924A (en) Amino pyridine, pharmaceuticals including anthem and their use in the manufacture of drugs for the treatment of cell proliferation
IL177717A0 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
IL218674A (en) Compounds that inhibit lrrk2 kinase activity, pharmacological preparations containing them, and their use in the preparation of Parkinson's disease drugs
IL199362A (en) Pyridopyrimidine Compounds, Pharmaceuticals, Compounds for Use as a Drug, and Compounds for Manufacture @ Drug
IL181524A (en) Heterocyclic compounds, pharmaceuticals containing them and their use in the preparation of drugs
IL233282A (en) Crystalline Forms of 5- (2,6-Di-4-Morpholinyl-4-Pyrimidinyl) -4-Trifluoromethylpyridine-2-Amine Monohydrochloride

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed